(Q48466380)

11 February 2018

title

Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio (English)

1 reference

11 February 2018

0 references

Livia Tossici-Bolt

1

1 reference

11 February 2018

Sandra M A Hoffmann

2

1 reference

11 February 2018

Paul M Kemp

3

1 reference

11 February 2018

Rajnikant L Mehta

4

1 reference

11 February 2018

John S Fleming

5

1 reference

11 February 2018

publication date

21 July 2006

1 reference

11 February 2018

number of pages

9

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

11 February 2018

volume

33

1 reference

11 February 2018

issue

12

1 reference

11 February 2018

page(s)

1491-1499

1 reference

11 February 2018

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-006-0155-X

Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-006-0155-X

Statistical methods for assessing agreement between two methods of clinical measurement

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-006-0155-X

Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline.

21 January 2018

1 reference

12 December 2020

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease

1 reference

12 December 2020

The specific uptake size index for quantifying radiopharmaceutical uptake

1 reference

12 December 2020

Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction

1 reference

12 December 2020

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

12 December 2020

Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.

1 reference

12 December 2020

Effects of scatter and attenuation correction on quantitative analysis of beta-CIT brain SPET.

1 reference

12 December 2020

1 reference

12 December 2020

Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.

1 reference

12 December 2020

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

1 reference

12 December 2020

Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain.

1 reference

12 December 2020

1 reference

12 December 2020

Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease

1 reference

12 December 2020

Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters.

1 reference

12 December 2020

Basal ganglia volume in adults with Down syndrome

1 reference

12 December 2020

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease

1 reference

12 December 2020

Influence of collimator characteristics on quantification in SPECT

1 reference

12 December 2020

Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems

1 reference

12 December 2020

[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease.

1 reference

12 December 2020

Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.

1 reference

12 December 2020

[123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls

1 reference

12 December 2020

One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.

1 reference

12 December 2020

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group

1 reference

12 December 2020

Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers

1 reference

12 December 2020

[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.

1 reference

12 December 2020

Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography

1 reference

12 December 2020

Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson's disease patients

1 reference

12 December 2020

Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients

1 reference

12 December 2020

Contribution of scatter and attenuation compensation to SPECT images of nonuniformly distributed brain activities

1 reference

12 December 2020

Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography

1 reference

12 December 2020

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

1 reference

12 December 2020

10.1007/S00259-006-0155-X

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018